On December 27, 2024, Adeoye Olukotun, a Director at Arrowhead Pharmaceuticals Inc (ARWR, Financial), sold 2,850 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now owns 36,740 shares of the company.
Arrowhead Pharmaceuticals Inc (ARWR) is a biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. The company leverages its proprietary Targeted RNAi Molecule (TRiM) platform to design and develop innovative therapies.
The insider transaction history for Arrowhead Pharmaceuticals Inc indicates that there have been 1 insider buy and 22 insider sells over the past year. This suggests a trend of more selling activity among insiders.
On the day of Adeoye Olukotun’s recent sell, shares of Arrowhead Pharmaceuticals Inc were trading at $20 each, giving the stock a market cap of $2.315 billion.
The stock's GF Value is estimated at $5.96, resulting in a price-to-GF-Value ratio of 3.36. This indicates that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on three factors:
- Historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
